Urogen Pharma (URGN) Coverage Initiated at Stifel Nicolaus

Share on StockTwits

Stifel Nicolaus started coverage on shares of Urogen Pharma (NASDAQ:URGN) in a report issued on Thursday morning, The Fly reports. The firm issued a buy rating and a $70.00 price objective on the stock.

A number of other equities analysts also recently issued reports on URGN. Oppenheimer set a $75.00 price target on shares of Urogen Pharma and gave the company a buy rating in a report on Tuesday, August 14th. Cowen reiterated a buy rating on shares of Urogen Pharma in a report on Tuesday, August 14th. Finally, ValuEngine upgraded shares of Urogen Pharma from a hold rating to a buy rating in a report on Saturday, June 2nd. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $59.60.

Shares of URGN opened at $46.16 on Thursday. Urogen Pharma has a 52-week low of $25.56 and a 52-week high of $69.57.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings results on Tuesday, August 14th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.89) by ($0.25). The company had revenue of $0.36 million during the quarter. Urogen Pharma had a negative net margin of 470.54% and a negative return on equity of 44.24%. analysts expect that Urogen Pharma will post -4.16 EPS for the current fiscal year.

Large investors have recently bought and sold shares of the business. Harel Insurance Investments & Financial Services Ltd. purchased a new position in Urogen Pharma during the 2nd quarter valued at about $129,000. Quantbot Technologies LP purchased a new position in Urogen Pharma during the 1st quarter valued at about $174,000. UBS Group AG increased its holdings in Urogen Pharma by 31.5% during the 1st quarter. UBS Group AG now owns 3,611 shares of the company’s stock valued at $180,000 after acquiring an additional 865 shares in the last quarter. DAFNA Capital Management LLC purchased a new position in Urogen Pharma during the 1st quarter valued at about $224,000. Finally, Jane Street Group LLC purchased a new position in Urogen Pharma during the 2nd quarter valued at about $227,000. Hedge funds and other institutional investors own 71.11% of the company’s stock.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

Recommended Story: Intrinsic Value

The Fly

Analyst Recommendations for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Griffon  Earns Neutral Rating from Analysts at Robert W. Baird
Griffon Earns Neutral Rating from Analysts at Robert W. Baird
Altisource Portfolio Solutions  Cut to Hold at BidaskClub
Altisource Portfolio Solutions Cut to Hold at BidaskClub
Urogen Pharma  Coverage Initiated at Stifel Nicolaus
Urogen Pharma Coverage Initiated at Stifel Nicolaus
Morgan Stanley Analysts Give FactSet Research Systems  a $210.00 Price Target
Morgan Stanley Analysts Give FactSet Research Systems a $210.00 Price Target
Morgan Stanley Analysts Give Msci  a $185.00 Price Target
Morgan Stanley Analysts Give Msci a $185.00 Price Target
Thomson Reuters  Lifted to “Overweight” at Morgan Stanley
Thomson Reuters Lifted to “Overweight” at Morgan Stanley


Leave a Reply

© 2006-2018 Ticker Report. Google+.